IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7373
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat ; volume:154 ; number:2 ; day:23 ; month:8 ; year:2021 ; pages:159-170 ; date:9.2021
Journal of neuro-oncology ; 154, Heft 2 (23.8.2021), 159-170, 9.2021
- Urheber
-
Sears, Thomas K.
Horbinski, Craig M.
Woolard, Kevin D.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11060-021-03829-0
- URN
-
urn:nbn:de:101:1-2021112418434642218329
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sears, Thomas K.
- Horbinski, Craig M.
- Woolard, Kevin D.
- SpringerLink (Online service)
Ähnliche Objekte (12)
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma
Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Biostructural, biochemical and biophysical studies of mutant IDH1
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
IDH1 mutation analysis – an example of putative glioma marker
The effects of BMP2 and the mechanisms involved in the invasion and angiogenesis of IDH1 mutant glioma cells
Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma
Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Biostructural, biochemical and biophysical studies of mutant IDH1
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
IDH1 mutation analysis – an example of putative glioma marker
The effects of BMP2 and the mechanisms involved in the invasion and angiogenesis of IDH1 mutant glioma cells
Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Investigating New Drug Options for Temozolomide Resistant IDH1 Mutant Glioma
5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma
Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Biostructural, biochemical and biophysical studies of mutant IDH1
Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
IDH1 mutation analysis – an example of putative glioma marker
The effects of BMP2 and the mechanisms involved in the invasion and angiogenesis of IDH1 mutant glioma cells